Introduction
============

Worldwide, breast cancer is the most frequent cancer among women. It affects more than one million women globally, accounting for more than 400,000 deaths annually \[[@B1]\]. In Iran as an Asian country, among women over 30, the incidence and prevalence rate of breast cancer is 22 and 120 per 100,000, respectively \[[@B2]\].

For a long time, biomedical scientists have been interested in finding ways to diagnose and to treat cancer patients at early stages. Research aimed at developing robust biomarkers and reliable assays, has made progress in the detection, diagnosis, and treatment of breast cancer. Only a limited number of biomarkers for breast cancer are currently available which assist in making breast cancer management decisions. Oncotype DX; a diagnostic panel commercially available; is indicated for specified breast cancer patients that predicts the risk of a patient experiencing a recurrence \[[@B3]\]. Estrogen receptor (ER), progesterone receptor (PR) and Her2/neu status are routinely measured to decide about hormone and targeted therapy. In addition, recommendations concerning the role of urokinase plasminogen activator (uPA) in detecting the invasive nature of the tumors have been recently added to the clinical guidelines \[[@B4]\].

Current routine assays for quantifying biomarkers, such as immunohistochemistry (IHC) and Enzyme-linked immunosorbent assay (ELISA) are approved and valid, and are reproducible between different laboratories \[[@B5]-[@B8]\]. However, unquantifiable results and long procedure time are among the drawbacks of these methods which have persuaded researchers to seek alternative modern molecular based techniques such as quantitative Real-Time PCR (Q-RT-PCR) \[[@B9],[@B10]\]. Q-RT-PCR is highly cost-effective, very fast, and one of the most sensitive and specific quantification methods for gene expression analysis \[[@B11],[@B12]\].

To be approved as a routine alternative method for conventional techniques; however, a number of validations are necessary for Q-RT-PCR including HK validation. Differences occurring during the steps of RNA quantification would be normalized by endogenous controls (ECs). There are large scale gene expression profiling studies in which hundreds of HKs were identified \[[@B13]-[@B15]\]. During the years of using Q-RT-PCR, based on this belief that housekeeping genes have uniform expression regardless of biological conditions, they have been applied for quantification. Several studies have revealed significant alterations in the expression of a number of ECs affecting validity of expression analysis \[[@B16]-[@B20]\]. Since reliability of ECs affects the accuracy of the normalized data, reference gene selection plays an important role in this matter. HK validations have been performed for a number of genes but, to the best of our knowledge, no report has been found for uPA in breast cancer. The uPA is involved in various biological processes. Along with some other genes, elevated expression of uPA in plasminogen activation system takes part in tumor cell invasion and metastatic process. High level expression of this marker represents an unfavorable prognostic factor for metastasis in breast cancer \[[@B6],[@B21]\]. The aim of the present study was to validate reference genes in order to select the most appropriate ECs for uPA quantification in breast cancer tissues.

Methods
=======

Breast tumor tissues (n = 40), normal tissues (n = 4) and normal adjacent tissues (n = 8), were taken from Iranian Center for Breast Cancer Biobank (ICBC-BB). According to the protocols followed by ICBC-BB, immediately after excisional biopsy or surgery, sample tissues were snap-frozen in liquid nitrogen and stored at -70°C. ICBC-BB is obliged to ethical guidelines and recommendations for biobanks on the storage and use of human biological samples. Clinical and histopathological features of patients are summarized in table [1](#T1){ref-type="table"}.

###### 

Clinical and histological data of malignant and normal adjacent breast tissues.

  Tissue type   Age   Size (mm)   Tumor stage   grade   Histological type   Menoposal status   ER   PR   Her2/neu   P53
  ------------- ----- ----------- ------------- ------- ------------------- ------------------ ---- ---- ---------- -----
  Adjacent      50                                                                                                  
  Adjacent      38                                                                             \-   \-   \-         \+
  Malignant     38    18          IIA           III     IDC                 pre                \+   \+   \-         
  Malignant     38    20                        III     IDC                 pre                3+   3+   2+         
  Malignant     58    35          IIIA          II      IDC                 post               \-   \-   \-         \+
  Malignant     80    10                        I       IDC                 post               \+   \+   \-         
  Malignant     54    30          IIB           II      IDC                 post                                    
  Adjacent                                                                                     \+   \+   3+         \+
  Malignant     40    25          IIB           II      IDC                 pre                \+   \+   \-         \+
  Malignant     35    20                        III     IDC                 post                                    
  Adjacent                                                                                                          
  Malignant                                                                                    \+   \+   \-         \+
  Malignant     52    21          IIA           II      IDC                 post               \+   \+   \-         \+
  Malignant                       III                   IDC                                    \+   \-   \-         \+
  Malignant     82    50          IIB           III     IDC                 post                                    
  Adjacent      43                                                                             \+   \+   \-         \-
  Malignant     50    50          IIA           II      IDC                 pre                3+   3+   \-         
  Malignant     44    20          IIIA          III     IDC                 pre                \+   \+   \-         
  Malignant     51    20          IIA           II      IDC                 post                                    
  Malignant                                                                                    \+   \+   \-         \-
  Malignant     37    60          IIIB          II      IDC                 post                                    
  Malignant     45                                      IDC                 pre                \+   \+   \-         
  Malignant     40    15          IB            II      IDC                 pre                \-   \-   \-         \+
  Malignant     42    20          IV            III     IDC                 pre                \+   \+   \-         \+
  Malignant     52    21          IIA           II      IDC                 post               \+   \+   \-         \-
  Malignant     50    8           IIA           II      IDC                 post               \+   \+   \-         
  Malignant     54    30          IIA           II      IDC                 post               \-   \-   \-         \-
  Malignant     45                IV                    IDC                 pre                                     
  Adjacent      45                                                                                                  
  Adjacent      40                                                                                                  
  Adjacent      52                                                                                                  
  Adjacent      42                                                                             \-   \-   \-         \-
  Malignant     53                                      IDC+DCIS            pre                \+   \+   3+         \-
  Malignant     34    10          IIB           II      IDC+DCIS            pre                \-   \-   \-         \+
  Malignant     56    38          IIB           II      IDC                 post               \+   \+   \-         
  Malignant     71    20          IV            II      IDC                 post               \-   \-   \-         \-
  Malignant     34    30          IIA           II      IDC                 pre                \+   \+   3+         
  Malignant     37                              II      IDC                 pre                \-   \-   \-         
  Malignant     48    30          IIB                   ILC                 pre                \+   \+   \-         \+
  Malignant     43    18          I                                         pre                \-   \+   \-         
  Malignant     45    20          II            II      ILC                 pre                \-   \-   3+         \+
  Malignant     39    100         IIIA          II      IDC                 pre                                     
  Malignant     34    60                        III     IDC                 pre                                     
  Malignant                                                                                                         
  Normal        25                                                                                                  
  Normal        38                                                                                                  
  Normal        32                                                                                                  
  Normal                                                                                       \+   \+   \-         \-
  Malignant     50    15          IB            I       IDC                 pre                \-   \-   3+         \+
  Malignant     32    10          IV            II      IDC                 pre                \+   \-   \-         
  Malignant     60    30          IV            II      IDC                 post               \+   \+   \-         \-
  Malignant     41    50          IV            I       IDC                 pre                                     

Stage grouping are based on American Joint Committee on Cancer (AJCC). Estrogen receptor(ER), progesterone receptor (PR), Her2/neu and P53 status are based on IHC results. Invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC)

Tissues (8-20 mg) were excised on dry ice and homogenized in 1 ml of RnxPlus (Cinnagen, Iran) to extract RNA according to manufacturer directions. Extracted RNAs were quantified by spectrophotometer (Hitachi, U-0080D, Japan) and the Absorbance ratio at 260/280 and 260/230 were measured to control the purity of the RNA. The integrity of RNA was confirmed by checking ribosomal RNA with electrophoresis on a 1% agarose gel. Then, 3.6 μg of RNA was treated with 18 unit of RNase-free DNase (Fermentas AB, Vilnius, Lithuania), 20 units of RNase inhibitor (Fermentas AB, Vilnius, Lithuania) and 2.4 μl of 25 mM MgCl2. The total volume of reaction was 30 μl. The reaction was incubated in 37°C for 15 min and then 90°C for 5 min to inactivate the DNase.1 μg of total RNA was transcribed to cDNA using Precision™reverse transcription kit (PrimerDesign Ltd, UK).

Six common housekeeping genes in breast cancer; TFRC, GUSB, GAPDH, ACTB, HPRT1 and RPLP0; were selected and their stability were examined in order to normalize expression of uPA. All primers and probes were designed using Gene Runner v.3.05 and confirmed with primer express 3.0 (Table [2](#T2){ref-type="table"}). Amplification efficiency for each primer was approximated using 10 fold cDNA serial dilutions and calculated using 7500 software system ver. 2.0. The serial dilutions were performed using pooled cDNA from 15 tumor cDNAs with equal proportion. CDNA synthesis was done as mentioned above.

###### 

Primer probe sets.

  Target   Accession No.   Sequence                         Melting TM   efficiency
  -------- --------------- -------------------------------- ------------ ------------
  GAPDH    NM_001002       F GAAGGTGAAGGTCGGAGTC            61.3         94
                           R GGGTGGAATCATATTGGAACA          63.2         
                           P ATTTGGTCGTATTGGGCGCCTGGT       74.9         
  TFRC     NM_003234       F ACCGGCACCATCAAGCT              64.5         94
                           R TGATCACGCCAGACTTTGC            65.2         
                           P TGAAAATTCATATGTCCCTCGTGAGGCT   72.1         
  RPLP0    NM_001002       F CGGACGAGGATATGGGATTTG          67.2         89
                           R AGAAGTAAGCCTTTATTTCCTTGTTT     64.7         
                           P TCACCAAAAAGCAACCAACTTAGCCAGT   72           
  GUSB     NM_000181       F GCGTTCCTTTTGCGAGGAGA           68.6         74
                           R GGTGGTATCAGTCTTGCTCAA          64.7         
                           P ACCAGGTATCCCCACTCAGTAGCCAAG    72           
  HPRT1    NM_000194       F TGGACTAATTATGGACAGGACTGAA      64.4         103
                           R GTAATCCAGCAGGTCAGCAA           62.8         
                           P CTTGCTCGAGATGTGATGAAGGAGATGG   73.7         
  UPA      NM_002658       F AGGGCAGCACTGTGAAATAGATAAGT     65.7         97
                           R CATGGTACGTTTGCTGAAGGA          64.8         
                           P TTACCGAGGAAAGGCCAGCACTGACA     75.3         
  ACTB     NM_001101       F CAGCAGATGTGGATCAGCAAG          65.9         95
                           R GCATTTGCGGTGGACGAT             67.1         
                           P AGGAGTATGACGAGTCCGGCCCC        73.8         

Probes were labeled with 5\' FAM and 3\' TAMRA.

Quantitative Real-Time PCR
--------------------------

Q-RT-PCR was carried out in triplicate format within the same 96-well plate for each sample using precision™ 2 × qPCR Mastermix (PrimerDesign Ltd, UK) in 20 μl reactions. Primer and probe concentrations were 0.5 μM and 0.3 μM, respectively. Fluorescent detection was performed using Applied Biosystems 7500 System. Data were analyzed using SDS software, vers.2.0 (Applied Biosystems).

Data analysis and endogenous control stability
----------------------------------------------

Raw data of Q-RT-PCR was analyzed using SDS software, vers.2.0 (Applied Biosystems). Samples with standard deviation greater than 0.5 from the mean threshold cycle (CT) of the replicates were excluded. In order to find the most stable housekeeping gene, the data were transformed to linear scale values with Excel. Analyses were done by pairwise comparison approach applying geNorm software\[[@B19]\] as well as combined estimation of the intra and inter group validation using NormFinder software\[[@B22]\]. UPA expression measurement was performed using ΔΔCT method with RPLP0 or combination of ACTB and TFRC as endogenous control. Comparison between the mean of each group was done using paired sample t-test (SPSS v.13) with 95% confidence interval.

Results
=======

Threshold cycle (CT) values of endogenous controls and uPA are shown in table [3](#T3){ref-type="table"}.

###### 

threshold cycle (CT) values of endogenous controls and uPA.

  Gene    CT Range   CT Min   CT Max   Mean ± s.e.m
  ------- ---------- -------- -------- --------------
  RPLP0   22.68      19.52    42.2     29.69 ± 0.81
  GUSB    8.61       27.59    36.2     31.99 ± 0.33
  TFRC    15.64      25.27    40.92    31.7 ± 0.5
  HPRT1   14.25      26.42    40.67    32.61 ± 0.43
  ACTB    14.05      16.93    30.98    25.1 ± 0.5
  GAPDH   19.2       22.69    41.89    29.3 ± 0.5
  UPA     10.65      28.13    38.78    31 ± 0.38

The range of threshold cycles (CT Range) was between 8.61 and 22.68 among endogenous candidate genes with a mean value ranging from 25.1 (± 0.5 s.e.m) for ACTB to 32.61(± 0.43 s.e.m) for GUSB. The maximum and minimum expression ranges were 22.68 cycles for GUSB and 8.61 cycles for ACTB respectively (Table3).

Data were analyzed using geNorm and NormFinder software programs. GeNorm calculates pairwise variation to find the most stable expressed ECs, and thereby computing the average expression stability value (M) and plotting it for each gene. In this study, RPLP0 and GAPDH revealed maximum M while TFRC demonstrated lowest M value (Figure [1](#F1){ref-type="fig"}). The most stable expressed gene was TFRC. The GeNorm software also calculates normalization factor (V); the point at which addition of extra endogenous control is unnecessary; to find the optimal number of required ECs. According to GeNorm software manual, recommended V-value cut-off was 0.15 but it was also mentioned that proposed value must not be taken as a too strict cut-off. In this study the V-values of using 3 and 4 ECs were calculated as 0.5 and 0.4, respectively (Figure [2](#F2){ref-type="fig"}).

![**GeNorm analysis of candidate genes: genes with low Average expression stability M which are plotted in the right side of x-axis indicate greater stability**.](1756-0500-4-215-1){#F1}

![**Determination of the optimal number of ECs for normalization: Inclusion of additional reference gene is not required for pairwise variation values (V value) below 0.15**.](1756-0500-4-215-2){#F2}

NormFinder software; an algorithm for identifying the optimal normalization gene among a set of candidates; was used to rank the set of candidate normalization genes according to their expression stability in a given sample set. In this study, NormFinder determined TFRC as the most stable EC Followed by GUSB and ACTB genes (Table [4](#T4){ref-type="table"}).

###### 

Stability values of reference genes using geNorm and NormFinder programs

             geNorm                                    NormFinder      
  ---------- --------------- ------------------------- --------------- ---------------
  **Rank**   **Gene name**   **Stability (M value)**   **Gene name**   **Stability**
                                                                       
  1          TFRC            2.846                     TFRC            0.796
  2          GUSB            2.902                     GUSB            1.007
  3          ACTB            2.984                     ACTB            1.130
  4          HPRT1           3.298                     HPRT1           1.799
  5          GAPDH           3.538                     GAPDH           1.984
  6          RPLP0           4.737                     RPLP0           2.966

Genes with lower number are more stable.

Statistical comparison of \"uPA expression results normalized with RPLP0\" in one group and \"the combination of TFRC and ACTB\" in another group showed significant difference in uPA expression amounts (p-value \< 0.05).

Discussion
==========

During recent years traditional attitudes towards therapeutic care has been replaced with individualized medicine especially in the cancer field. It is recommended to assess approved markers in order to select the best therapeutic models instead of blind administration of similar regimens for all patients.

Among current systems, gene expression profiling plays a major role in tailoring treatment to the individual strategy. Despite the accuracy of routinely used approved methods for detection of biomarkers such as IHC for measurement of Her2 and ER biomarkers and ELISA for uPA, there are still disadvantages. For instance, ELISA requires a substantial amount of tissue and small tissues of early stage cancer would be difficult to be analyzed \[[@B4]\]. Several studies using various types of design have been conducted to determine whether novel molecular techniques like Q-RT-PCR may be added to routine approved methods for detection and quantification of biomarkers \[[@B23]-[@B31]\].

To our knowledge this is the first study on determining reference gene in breast cancer for quantification of uPA. We found that TFRC and ACTB is the best combination of two genes with the greatest expression stability. GeNorm and NormFinder without sub grouping had a similar performance in detecting the most and the least stable genes. TFRC and RPLP0 were the most and the least satiable genes. GAPDH and ACTB were among the least and the most stable genes which a in concordance with other breast cancer studies \[[@B17],[@B32]-[@B35]\]. Both softwares recognized the same order of stability for all of the genes (Table4). Other Studies suggest different genes. Mc Neill et al in a study for ER quantification, suggested MRPL19 and PPIA as the most stable and RPLP0 as the least stable genes, while in the study by Lyng et al TBP, RPLP0 and PUM1 were recommend for normalization \[[@B36]\]. Moreover, 18S rRNA and HPRT1 have been suggested for breast cancer normalization in quantification of Her2/neu \[[@B18],[@B34]\].

Housekeeping selection is a critical step in Q-RT-PCR analysis. The idea that housekeeping genes (ECs) pose constant expression in different cells may influence their selection in various studies. In the study by Mc Neill et al the data of housekeeping gene selection in colorectal and ovarian cancer was used to decide about selection of an EC for breast cancer \[[@B17]\]. It should be noted that instability of one housekeeping gene in specific cancer does not mean instability in other cancers. The important key is that housekeeping gene expression patterns are influenced by cancer mechanism and EC selections should be made for each cancer separately \[[@B37],[@B38]\]. Housekeeping generalization may result in inappropriate set of ECs because some genes may be included or excluded erroneously based on other cancer evidences.

It is also noteworthy that various experiment conditions in the studies may change the expression of the housekeeping genes. As a result, dissimilar genes may be found as the best reference for normalization in different studies with different conditions.

Conclusions
===========

To conclude, it appears that identifying a *universal housekeeping*for gene expression analysis is far from reality. Thus, stability of controls should be checked based on the tissue type and experiment design. On the basis of our findings, we suggest that TFRC is the most stable EC, ACTB and TFRC is the best combination of two reference genes to quantify uPA, and that using RPLP0 and GAPDH are not recommendable for breast cancer. The authors also suggest testing with large sample size and more candidate reference gene to find more stable ECs.
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